Question for the board: Would the current data
Post# of 148187
Would the current data from combo trials of Leronlimab allow CYDY to apply for approval in other countries?
I’ve read about other biotechs conducting their studies and even seeking approval in foreign markets first because of the bureaucracy of the FDA. If the market for leronlimab is larger in Europe and other markets, why not take the data there and apply for approval?